Promising patient data surrounding this compound, specifically the 120mg formulation referred to as ZPHC, indicate a considerable effect on body mass loss and related metabolic factors. Researchers anticipate that this innovative compound, influencing both GLP-1 and GIP receptors , has the potential to represent a substantial advance in the treatm